Certara, Inc. · NASDAQ:CERT
Certara — Blueprint for Biotech Success webinar (September 2025)
27 slides from Certara's conference presentation, September 2025
Slide 1: Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value
Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value
Slide 2: Webinar speakers
Webinar speakers Kevin Hershberger, BPharm, MBA Colin Callaghan, BPharm, MBA Max Vargas, PhD, MBA Vice President Nonclinical Senior Director, Program Leadership Vice President, Evidence & Access Development Sciences Certara Strategy Certara Certara
Slide 3: Agenda topics
Agenda topics • Laying the Foundation for Early Development Success • Commercial Considerations for Early Development – Setting the Destination • Securing Biotech Investment: Strategies for Success © Copyright 2025 Certara, Inc. All rights reserved. 3
Slide 4: Laying the Foundation for Early Development Success
Laying the Foundation for Early Development Success Kevin Hershberger, BPharm, MBA Vice President Nonclinical Development Sciences Certara Drug Development Solutions 4
Slide 5: The Value of Better Decisions
The Value of Better Decisions High attrition rates, lengthy development timelines, ballooning costs continue to plague the industry. Optimizing early development plans with drug development and biosimulation experts can mitigate these program risks. Number of Drug Phase Failure Rate % Dev Cost Cost
Slide 6: Potential savings from a 3% increase in process efficiency
≈$300 Making well-informed decisions earlier, increases efficiency and transforms million* attrition cost to reinvestment opportunities. • Save years of time Per drug, the potential savings from • Optimize resources for the most valuable projects just a 3% increase in process • Gain deeper insights
Slide 7: Eroom's Law
Eroom’s Law Moore's Law vs Eroom's Law 1E+09 100000000 Eroom’s Law is the observation 30 Transistor # per $1B 10000000 that the cost of developing new NME per $1B 1000000 drugs is increasing exponentially, out pacing the productivity of 100000 drug discovery. The reverse 10000 is Moore's Law, which
Slide 8: Early Development Crucial for Success
Early Development Crucial for Success • Setting the Stage • Strategy, Timeline, and Financial Planning (Decision Point Map) o Target Product Profile (Decision Guide) - Quantitatively aligning on parameters that are most o Ensure critical requirements are met and important the most appropriate regula
Slide 9: Development is a team sport requiring everyone to pull/push in the same direction
Development is a team sport requiring everyone to pull/push in the same direction. Illustrative example: Team flexes based on program needs Functional Areas ✓ Program management (dedicated lead) ✓ Clinical pharmacology ✓ Pharmacometrics ✓ Regulatory strategy Team Size ✓ Biostatistics ✓ Market access
Slide 10: Certara's methodologies deliver greater certainty from molecules to market
Certara’s methodologies are aimed to deliver greater certainty from molecules to market. Design programs Leveraging All Improving Available Data Decision Making Combining deep regulatory insight, Utilizing MIDD to Maximizing scientific rigor, and address questions, information from cross-functional
Slide 11: Commercial Considerations for Early Development – Setting the Destination
Commercial Considerations for Early Development – Setting the Destination Maximilian Vargas, PhD, MBA Vice President, Evidence & Access Strategy Certara 11
Slide 12: Why Early Clinical Development Matters Commercially
Why Early Clinical Development Matters Commercially • Drug development isn’t only a scientific journey – it’s a business investment • Commercial thinking should start early, with the end in mind o What does a minimum viable product look like? And an optimal one? o What are the competitive differenti
Slide 13: Value Creation During Development De-risk & Proof of Hope
Value Creation During Development De-risk & Proof of Hope How biotech valuation grows across phases Phase 1 Phase 2 Phase 3 Phase 4 Market Clinical Trials Clinical Trials Clinical Trials Clinical Trials Launch & Growth Company First human Efficacy FDA/EMA Large trials, FDA valuation trials, safety t
Slide 14: Example target product profile
TPP Section Minimum Criteria Target Criteria How to De-Risk in Early Dev ? Example target product profile Indication: Approved for slowing Approved for disease Phase II/III Trials Treatment of idiopathic disease progression in IPF modification and Prior knowledge/in silico pulmonary fibrosis (IPF) s
Slide 15: Value Creation in Early Development
Value Creation in Early Development • TPP Alignment – Probability of Hitting TPP • Proof of developability o Can you create a stable formulation at a reasonable price that will deliver the drug effectively o Acceptable dose and dosing frequency o Early safety and tolerability o Embrace the power of
Slide 16: Translating Phase 1 Data to Competitive Differentiation with MBMA
Translating Phase 1 Data to Competitive Differentiation with MBMA EXAMPLE Third-generation antisense oligonucleotide targeting PCSK9. In a Phase 1 study, subcutaneous dosing produced >90% suppression within one week, sustained for ~4 weeks, LDL-C levels dropped in a dose-dependent manner. The drug w
Slide 17: Conclusions
Conclusions • Early clinical decisions shape long-term commercial success — including valuation, access, and differentiation • TPP alignment and stakeholder input must start in Phase I, not wait for later-stage programs • Cross-functional integration (clinical, regulatory, commercial) is essential f
Slide 18: Securing Biotech Investment: Strategies for Success
Securing Biotech Investment: Strategies for Success Colin Callaghan, BPharm, MBA Senior Director, R&D Program Leadership Certara 18
Slide 19: Factors Driving Investment Attractiveness
Factors Driving Value Proposition Investment What you have inc. Technology Attractiveness What you intend to do with it What are the advantages What is the Strategy What is the potential return Confidence In Delivery Team Access to resources Innovation Plan Budget 19
Slide 20: A Well-Conceived Strategy Increases Value Potential
A Well-Conceived Strategy Increases Value Potential Clinical Development: Regulatory: special programs, indication, biomarker, special region(s), PRS population, PIs / KOLs Communication and News DATA Risk Identification and flow: long range view, Mitigation: both internal target best events to (pro
Slide 21: Great! Can You Do It? Increasing Confidence In Delivery
Great! Can You Do It? Increasing Confidence In Delivery Better data faster? Choosing the right vendors is critical Great plans: • Anticipate Your Team is #1 • Align • Communicate © Copyright 2025 Certara, Inc. All rights reserved. 21
Slide 22: Catalyze your funding efforts with an investor-ready strategy
Partner with Certara to deliver: Catalyze your 1. A more compelling scientific and business case funding efforts 2. based on medical need and commercial value Strong positioning based on competitive with an investor- 3. landscape and market analysis A development plan/trajectory that leverages ready
Slide 23: Certara's early development program: 3 packages
Certara’s early development program is provided as a series of 3 packages that are tailored to your in-house expertise/capabilities and program needs 1 Certara does not provide manufacturing or wet lab services but will provide oversight, coordination, and timeline management Stage Supporting Functi
Slide 24: Certara Early Development: Expertise for lead candidate selection through FIH
Certara Early Development: Expertise, for lead candidate selection through first-in-human (FIH) trial Reduce tactical complexity with a sponsor-side partner that provides flexible, scalable support through a single point of contact Streamlined access to cross-functional expertise High complexity Wit
Slide 25: Questions?
Questions? Contact us for a complimentary strategy session with one of our experts.
Slide 26: Contact our speakers
Contact our speakers Kevin Hershberger, BPharm, MBA Colin Callaghan, BPharm, MBA Max Vargas, PhD, MBA Vice President Nonclinical Senior Director, Program Leadership Vice President, Evidence & Access Development Sciences Certara Strategy Certara Certara kevin.hershberger@certara.com colin.callaghan@c
Slide 27: www.certara.com
www.certara.com 27
Certara — Blueprint for Biotech Success webinar (September 2025) on 6ix